Biotech Giant Argenx Halts Major Trial for Autoimmune Drug

2026-10-08 biotech

Ghent, Thursday 8 October 2026
Argenx has halted its late-stage trial for Sjögren’s disease after an independent panel deemed the drug ineffective, striking a blow to the biotech firm’s expansion plans.

A Decision Driven by Futility

On 7 October 2026, the global immunology innovator argenx SE announced the discontinuation of its Phase 3 UNITY clinical trial [2][3]. The study was evaluating the efficacy, safety, and tolerability of subcutaneous efgartigimod (efgartigimod alfa and hyaluronidase-qvfc) in adults suffering from moderate-to-severe Sjögren’s disease [2][3]. The decision to halt the study followed a clear recommendation from an Independent Data Monitoring Committee (IDMC), which conducted an interim analysis and concluded that the trial was highly unlikely to meet its primary efficacy endpoint [2][3]. Encouragingly, the safety profile of efgartigimod remained consistent with previous clinical data, and no new safety signals were identified during the trial [2][3].

Strict Trial Parameters and Design

The UNITY study was designed as a randomized, double-blind, placebo-controlled, multicentre trial [2][3]. To qualify for enrolment, patients had to meet rigorous criteria: they must have fulfilled the 2016 ACR/EULAR classification criteria for primary Sjögren’s disease, tested positive for anti-Ro/SSA autoantibodies, and exhibited moderate-to-severe systemic disease activity, defined as a clinical EULAR Sjögren’s Syndrome Disease Activity Index (clinESSDAI) score of 6 or higher [2][3]. The primary clinical benchmark was the change from baseline in systemic disease activity measured by the clinESSDAI index at Week 48 [2][3]. Following the study’s termination and subsequent database lock, argenx plans to carry out a comprehensive analysis of the collected data to glean insights that might guide future therapeutic research [2][3].

The Complexity of Sjögren’s Disease

Sjögren’s disease is a chronic, systemic autoimmune inflammatory disorder characterized by the immune-mediated destruction of the body’s exocrine glands [6]. The disease carries a substantial gender bias, predominantly affecting women, with an incidence ratio of 9 female-to-male [6]. Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx, expressed deep disappointment regarding the trial’s outcome, particularly for patients waiting for disease-modifying therapies [2][3]. Truyen noted that Sjögren’s remains one of the most heterogeneous and complex conditions in modern immunology, making the biological pathways exceptionally difficult to untangle [2][3].

Market Impact and Portfolio Resilience

Despite this pipeline setback, subcutaneous efgartigimod remains a highly successful commercial asset for argenx [1][6]. The therapeutic is already approved for other serious autoimmune indications, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy [6]. However, the announcement of the trial’s discontinuation on 7 October 2026 inevitably pressured investor sentiment, leading to a decline in argenx’s share price on Euronext Brussels [1]. Moving forward, argenx intends to focus its resources on its other therapeutic franchises and continues to actively evaluate the broader clinical potential of efgartigimod across a range of other serious autoimmune conditions [1][5].

Sources & Ecosystem Partners

Clinical trials Biotech pipeline